Day: October 20, 2025

VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) — EnviroGold Global Limited (CSE: NVRO | OTCQB: ESGLF | FSE: YGK), (“EnviroGold,” or the “Company”) is pleased to announce that it has successfully closed its upsized $7.5 million non-brokered private placement, increased from the original $5 million target following significant strategic and institutional investor demand. “We’re delighted to close this significantly oversubscribed financing, which underscores the growing institutional and shareholder confidence in our technology, our commercialisation roadmap, and our long-term growth strategy,” said David Cam, Chief Executive Officer of the Company. “The inclusion of Pala Investments, a respected global investment firm focused on the resource and clean-technology sectors, marks an important milestone for EnviroGold....

BNP PARIBAS STATEMENT ON SUDAN LITIGATION PRESS RELEASE Paris, 20 October 2025 BNP Paribas has very clearly stated its unwavering intention to appeal. There is no doubt whatsoever that the Bank will fight this case and use all recourses available to it.   We strongly believe this verdict should be overturned on appeal. Once again, BNP Paribas reaffirms that this result is clearly wrong and ignores important evidence the bank was not permitted to introduce. We are going to pursue all available avenues to contest this judgment.  Furthermore, this verdict is specific to these three plaintiffs and should not have broader application.   Any attempt to extrapolate is necessarily wrong as is any speculation regarding a potential settlement. The Bank considers that it does not have any pressure to settle this case. About BNP Paribas Leader in...

Castellum, Inc. to Attend the 2025 Maxim Growth SummitCastellum, Inc. (NYSE-American: CTM) (“Castellum” or “CTM”), a cybersecurity, electronic warfare, and software engineering services company focused on the federal government, is excited to announce its participation in the upcoming 2025 Maxim Growth Summit, taking place from October 22nd to 23rd at The Hard Rock Hotel NYC – https://castellumus.com/ & http://www.maximgrp.com/2025-growth-summitVIENNA, Va., Oct. 20, 2025 (GLOBE NEWSWIRE) — Castellum, Inc. (NYSE-American: CTM) (“Castellum” or “CTM”), a cybersecurity, electronic warfare, and software engineering services company focused on the federal government, is excited to announce its participation in the upcoming 2025 Maxim Growth Summit, taking place from October 22nd to 23rd at The Hard Rock Hotel NYC....

Trondheim, 20 October 2025 NORBIT today announces that segment PIR has received a new contract manufacturing order, valued at approximately NOK 120 million from an undisclosed European client in the defence and security sector. Deliveries under the order are scheduled for late 2025 and early 2026. The contract follows another recently received award of approximately NOK 100 million for initial deliveries early first quarter 2026. “We are proud to see that our strategic partnerships in this domain continue to evolve. In today’s complex geopolitical landscape, the strong momentum in the defence and security industry endures. As an industrial scaling partner, we have taken the necessary steps to build capacity and inventory through close collaboration with our clients, ensuring preparedness to deliver as opportunities mature. Positioning...

Aspocomp Group Plc, Investor News, October 20, 2025, at 10:00 a.m. Finnish time Aspocomp will publish its January-September Interim Report 2025 on Thursday, October 30, 2025, at around 9:00 a.m. Finnish time. Aspocomp’s CEO Manu Skyttä will present January-September Interim Report 2025 in a webcast on the same day starting at 1:00 p.m. Finnish time. The webcast will be held in Finnish and can be accessed at https://aspocomp.events.inderes.com/q3-2025. Questions are requested to be submitted in writing via the chat functionality of the webcast portal. The presentation material in English, and a recording of the webcast (in Finnish) will be available at Aspocomp’s. For further information, please contact Manu Skyttä, President and CEO,tel. +358 20 775 6860, manu.skytta(at)aspocomp.com. Aspocomp – heart of your technology A printed circuit...

Antwerp, Oct. 20, 2025 (GLOBE NEWSWIRE) — CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMB.TECH”) has mandated Danske Bank, DNB Carnegie, Nordea Bank and Pareto Securities to arrange a series of fixed income investor meetings commencing today, October 20, 2025.   Following the investor meetings a USD denominated five-year senior unsecured bond issue may follow, subject to inter alia market conditions. The proceeds from the potential bond issue will be used for general corporate purposes of the Group including refinancing of existing debt.  For additional information please contact our head of Investor Relations Joris Daman – joris.daman@cmb.tech  About CMB.TECH CMB.TECH is one of the largest listed, diversified and future-proof maritime groups in the world with a fleet of about 250 vessels:...

Antwerp, Oct. 20, 2025 (GLOBE NEWSWIRE) — CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMB.TECH”) provides a market update. During Q3 and Q4 to date, CMB.TECH has continued its fleet rejuvenation strategy with the sale of two older vessels and the delivery of five newbuild vessels.   Fleet update  Deliveries  CMB.TECH took delivery of 5 newbuilding vessels in Q3 and Q4 to date:  Eco-Newcastlemaxes: Mineral Slovensko and Mineral Slovenija Chemical tanker: Bochem Santos CTV: Windcat 58 CSOV: Windcat Rotterdam Sales & TC updates  Euronav   CMB.TECH has sold the VLCC Dalma (2007, 306,543 dwt). The sale will generate a capital gain of 26.7 million USD. The vessel will be delivered to its new owner during Q4 2025.   The time charter of the VLCC Donoussa (2016, 299,999...

  ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumorsNew AlphaMedix data showed sustained and clinically meaningful responses across both RLT-naïve and RLT-exposed patients with unresectable or metastatic GEP-NETs First phase 2 study to evaluate TAT with lead-212 supporting its potential to address high unmet medical needs in difficult-to-treat, rare cancers Phase 2 study met all primary efficacy endpoints and was presented across two oral presentations at the 2025 ESMO Congress in Berlin, GermanyParis, October 20, 2025. New data from the ALPHAMEDIX-02 phase 2 study (clinical study identifier: NCT05153772) evaluating AlphaMedix (212Pb-DOTAMTATE), an investigational somatostatin receptor (SSTR) targeted alpha therapy (TAT) using the lead-212...

ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumorsNew AlphaMedix data showed sustained and clinically meaningful responses across both RLT-naïve and RLT-exposed patients with unresectable or metastatic GEP-NETs First phase 2 study to evaluate TAT with lead-212 supporting its potential to address high unmet medical needs in difficult-to-treat, rare cancers Phase 2 study met all primary efficacy endpoints and was presented across two oral presentations at the 2025 ESMO Congress in Berlin, GermanyParis, October 20, 2025. New data from the ALPHAMEDIX-02 phase 2 study (clinical study identifier: NCT05153772) evaluating AlphaMedix (212Pb-DOTAMTATE), an investigational somatostatin receptor (SSTR) targeted alpha therapy (TAT) using the lead-212 isotope,...

This announcement contains information on transactions of the acquisition of own shares of AB Artea bankas (the Bank) carried during the period specified below under the Bank’s own share buy-back programme announced on 01 October 2025.  The period during which the acquisition of the Bank’s own shares under the programme was carried out – 06.10.2025 – 17.10.2025.  Period covered by this periodic report – 13.10.2025 – 17.10.2025.  Other information: Transaction overview Date  Total number of shares purchased on the day ( units)  Weighted average price (EUR)  Total value of transactions (EUR) 2025.10.13 78,000 0.833 64,972.002025.10.14 78,000 0.831 64,818.002025.10.15 78,000 0.828 64,622.012025.10.16 78,000 0.833 65,004.002025.10.17 78,000 0.834 65,024.00Total acquired during the current week  390,000 0.832 324,440.01Total...